Viusid, a nutritional supplement, in combination with interferon α-2b and ribavirin in patients with chronic hepatitis C

Liver International

Volumn 27, Issue 2, 2007, Pages 247-259

  Vilar Gomez, Eduardo ^a   Gra Oramas, Bienvenido ^a   Arus Soler, Enrique ^a   Llanio Navarro, Raimundo ^a   Ruenes Domech, Caridad ^a  

^a INSTITUTO DE GASTROENTEROLOGÍA   (Cuba)

Author keywords

Antiviral therapy; Chronichepatitis C; Complementary therapy; Nutritional supplement; Randomized controlled trial

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; ARGININE; ASCORBIC ACID; CYANOCOBALAMIN; FOLIC ACID; GLUCOSAMINE; GLYCINE; GLYCYRRHIZIC ACID; HEBERON; HEMOGLOBIN; MALIC ACID; PANTOTHENATE CALCIUM; PYRIDOXAL; RIBAVIRIN; SHORT ACTING DRUG; UNCLASSIFIED DRUG; VIRUS RNA; VIUSID; ZINC SULFATE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHENIA; BACTERIAL ENDOCARDITIS; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; HYPERTHYROIDISM; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NONHUMAN; OPEN STUDY; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PILOT STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS LOAD; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; LIVER; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; ALANINE TRANSAMINASE; ANEMIA; ANTIVIRAL AGENTS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER; MALE; MIDDLE AGED; RIBAVIRIN; TREATMENT OUTCOME;

EID: 34247592978     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01411.x     Document Type: Article

References (57)

1. Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001; 358: 958-65.
2. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a (40 KD) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled multicenter study. N Engl J Med 2002; 347: 975-82.
3. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
4. Wintergerst ES, Maggini S, Hornig DH. Immune-enhancing role of vitamin C and zinc and effect on clinical conditions. Ann Nutr Metab 2006; 50: 85-94.
5. Duarte TL, Lunec J. Review: When is an antioxidant not an antioxidant? a review of novel actions and reactions of vitamin C. Free Radic Res 2005; 39: 671-86.
6. Cuevas LE, Koyanagi A. Zinc and infection: A review. Ann Trop Paediatr 2005; 25: 149-60.
7. Oteiza PI, Mackenzie GG. Zinc, oxidant-triggered cell signaling, and human health. Mol Aspects Med 2005; 26: 245-55.
8. Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 2005; 26: 391-404.
9. Miyaji C, Miyakawa R, Watanabe H, et al. Mechanism underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glycyrrhizin. Int Immunopharmacol 2002; 2: 1079-86.
10. van Rossum TG, Vulto AG, Hop WC, et al. Glycyrrhizin-induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 2432-7.
11. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-500.
12. Look MP, Gerard A, Rao GS, et al. Interferon/antioxidant combination therapy for chronic hepatitis C - a controlled pilot trial. Antiviral Res 1999; 43: 113-22.
13. Ideo G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: A randomised, multicentre study. Eur J Gastroenterol Hepatol 1999; 11: 1203-7.
14. Grant PR, Black A, Garcia N, et al. Combination therapy with interferon-alpha plus N -acetyl cysteine for chronic hepatitis C: A placebo controlled double blind multicentre study. J Med Virol 2000; 61: 439-42.
15. Takagi H, Nagamine T, Abe T, et al. Zinc supplementation enhances the response to interferon therapy in patients with chronic hepatitis C. J Viral Hepat 2001; 8: 367-71.
16. Fujiyama S, Chikazawa H, Honda Y, et al. Treatment of chronic active hepatitis C with interferon alpha 2b alone and in combination with Stronger Neo Minophagen C. Biother Jpn 1998; 12: 1495-513.
17. Suzuki Y, Ikeda K, Saitoh S, et al. A prospective randomised administration of stronger neo minophagen C as an adjuvant therapy for chronic hepatitis type C treated with interferon. Acta Hepatol Jpn 1996; 37: 363-7.
18. Ishak KG, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
19. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
20. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
21. Heathcote EJ, Shiffman ML, Cooksley GE, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 1673-80.
22. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
23. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with to interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001; 33: 433-8.
24. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-72.
25. Craxi A, Camma C, Giunta M. Definitions of response to antiviral therapy in chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 160-7.
26. Lindsay KL. Introduction to therapy of hepatitis C. Hepatology 2002; 36 (Suppl.): 114-20.
27. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of the liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
28. Sobesky R, Mathurin P, Charlotte F, et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view. Gastroenterology 1999; 116: 378-86.
29. Poynard T, McHutchinson J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.
30. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.
31. Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
32. Cammà C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of individual patient data. Hepatology 2004; 39: 333-42.
33. Pockros PJ, Carithers R, PEGASYS International Study Group, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: A multicenter, randomized controlled trial. Am J Gastroenterol 2004; 99: 1298-305.
34. Abe Y, Ueda T, Kato T, Kohli Y. Effectiveness of interferon, glycyrrhizin combination therapy in patients with chronic hepatitis C. Nippon Rinsho 1994; 52: 1817-22.
35. Melhen A, Stern M, Shibolet O, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of phase I clinical trial. J Clin Gastroenterol 2005; 39: 737-42.
36. Abe M, Akbar F, Hasebe A, et al. Glycyrrhicin enlaces interleukin-10 production by liver dendritic cells in mice with hepatitis. J Gastroenterol 2003; 38: 962-7.
37. Yoshikawa M, Toyohara M, Ueda S, et al. Glycyrrhicin inhibits TNF induced, but no Fas-mediated, apoptosis in human hepatoblastoma line HepG2. Biol Pharm Bull 1999; 22: 951-5.
38. Kimura M, Inoue H, Hirabayashi K, et al. Glycyrrhicin and some analogues induce growth of primary cultured adults rat hepatocytes via epidermal growth factor receptors. Eur J Pharmacol 2001; 431: 151-61.
39. 2-IIA activity in vitro. Biol Pharm Bull 2001; 24: 1004-8.
40. DeMaria N, Colantoni A, Fagiuoli S, et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Rad Biol Med 1996; 21: 291-5.
41. Romero MJ, Bosch-Morell F, Romero B, et al. Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients. Free Rad Biol Med 1998; 25: 993-7.
42. Farinati F, Cardin R, DeMarie N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
43. Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997; 50: 401-6.
44. Boya P, Pena ADL, Beloqui O, et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol 1999; 31: 808-14.
45. Larrea E, Beloqui O, Munoz-Navas MA, et al. Superoxide dismutase in patients with hepatitis C virus infection. Free Rad Biol Med 1998; 24: 1235-41.
46. Houglum K, Venkatramani A, Lyche K, et al. A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 1997; 113: 1069-73.
47. Coon JT, Ernst E. Complementary and alternative therapies in the treatment of chronic hepatitis C. J Hepatol 2004; 40: 491-500.
48. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26: 473-7.
49. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
50. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123: 141-51.
51. Brass CA. Do antioxidants ameliorate ribavirin related anemia in HCV patients? [abstracts]. Gastroenterology 1999; 1192-3.
52. Bacon BR. and others. Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin. Digestive Diseases Week. May 15-20, 2004. New Orleans, LA. Abstract 1150.
53. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 2491-9.
54. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: A prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 1302-11.
55. Campbell MS, Sun JC, Lee BY, et al. Administration of erythropoietin for hepatitis C treatment-related anemia is not cost effective. Program and abstracts of the 56th Annual Meeting of the American Association for the Study of the Liver Diseases; November 11-15, 2005; San Francisco, CA. Abstract 379.
56. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000; 31: 997-1004.
57. Viusid information and clinical presentation. Spain: Catalysis Hepatitis and AIDS Research, 2005. (Accessed December 12, 2005, at: http://www.viusid.com)